Cardio-TriTest v6.5

The Cardio-TriTest v6.5 aims to enhance cardiovascular diagnostic capabilities for general practitioners by simultaneously acquiring and synchronizing electrocardiograph, phonocardiograph, and mechanocardiograph data. This non-invasive device utilizes integrated Kombi-Sensors and standardized methodologies for each signal type, presenting a correlated view of cardiac electrical activity, sounds, and mechanical vibrations to aid in a more comprehensive heart health assessment.

The Cardio-TriTest v6.5 is a non-invasive diagnostic tool designed to assist general practitioners in assessing cardiovascular health by integrating three bio-signal modalities. It concurrently captures 12-Lead Electrocardiograph (ECG) data, 4-Lead Phonocardiograph (PCG) acoustic heart sounds, and 4-Lead Mechanocardiograph (MCG) cardiac vibrations during a single procedure. The core innovation lies in synchronizing these three distinct data streams onto a unified timeline, enabling physicians to visually correlate cardiac electrical activity, sounds (like S1/S2 and murmurs), and mechanical movements for a potentially broader diagnostic insight. The device is intended for adult patients (20 years and older) in clinical settings, excluding pediatric and intensive care unit populations, and requires physician interpretation. The system employs "Kombi-Sensors" that combine PCG and MCG functionalities, placed at standard thoracic auscultation points. The ECG component adheres to EN IEC 60601-2-25, while the PCG records acoustic waveforms and the MCG captures mechanical vibrations. Data is sampled at 4000 Hz for all analog signals and transferred via USB 3.0 to a Windows-based PC. While offering features like digital filtering and identification of basic heart sounds, the device focuses on synchronized data presentation rather than advanced automated analysis. Its safety and performance are affirmed through compliance with relevant standards such as IEC 60601-1, distinguishing it as an updated iteration of a previous model with changes in operating system compatibility, recording time presets, and sampling rates.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the synchronized presentation of ECG, PCG, and MCG data specifically enhance diagnostic accuracy for conditions where one modality alone might be insufficient or ambiguous?; What is the quantitative impact of the increased sampling rate (to 4000 Hz for all analog signals) on the resolution and diagnostic utility of the ECG, PCG, and MCG waveforms compared to the previous version?; Are there specific cardiovascular conditions or patient subgroups for which the Cardio-TriTest v6.5 is expected to offer the most significant diagnostic advantages over traditional separate ECG, PCG, or MCG assessments?; Given the device's reliance on visual correlation by general practitioners, what training or interpretive guidelines are provided to ensure consistent and accurate utilization of the combined data?; What are the performance characteristics (e.g., sensitivity, specificity) of the PCG component in detecting various types of heart murmurs when compared to auscultation by an experienced cardiologist or echocardiography?